Background
==========

May Measurement Month 2017 (MMM17) was the first of a series of annual campaigns initiated by the International Society of Hypertension (ISH). MMM was created to address the issue of lack of awareness of hypertension, which the PURE study[@suz055-B1] had shown was the single issue with the biggest capacity for improvement in terms of reducing the mortality, morbidity, and burden of disease associated with raised blood pressure (BP). The primary aim of MMM17 was to raise awareness of high BP through a multinational screening campaign and cross-sectional survey of BP in adults across the world.

MMM17: summary
==============

The methods and results have been fully reported elsewhere[@suz055-B2] but in essence, using convenience sampling and volunteer investigators, three sitting BP measurements of volunteer adults (≥18 years) who ideally had not had their BP measured in the previous year, were recorded along with limited data on demographic, lifestyle, and environmental factors. Hypertension was defined as a systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg, or in those who reported taking anti-hypertensive medication.

Over 1.2 million screenees from 80 countries were included and analysed, of whom about one-third were hypertensive. Among these hypertensives over 100 000 people were not on BP-lowering treatment and over 150 000 people who were on treatment for hypertension had inadequately controlled BP. Thirty-four of the collaborating countries reported that MMM17 was the largest BP screening ever to take place in their country.

From global to national data
============================

In view of the success of MMM17 at a national level, it was decided to collate the individual national data of those countries who had screened at least 2500 adults, to generate a unique resource of BP data, presented in this *European Heart Journal* Supplement. Table [1](#suz055-T1){ref-type="table"} displays an overview of the results for the 39 countries in the supplement, including number of participants, numbers with hypertension, and the proportions of those with hypertension who were untreated, on treatment and uncontrolled and on treatment and controlled. A supplementary table with countries of over 200 participants, not in this supplement, can be found online.

###### 

Numbers with hypertension and proportion on treatment, controlled and uncontrolled for countries in supplement

  Country                                         Total number  Number with hypertension   Percentage with hypertension    Percentage of individuals with hypertension:          
  ---------------------------------------------- -------------- -------------------------- ------------------------------ ---------------------------------------------- ------- -------
  Philippines                                       271 604     91994                      34.3%                                              31.2%                       27.3%   38.3%
  China                                             125 236     32089                      25.7%                                              35.7%                       23.0%   41.0%
  India [\*](#tblfn1){ref-type="table-fn"}          122 685     38974                      31.8%                                              55.9%                       36.4%   7.7%
  Indonesia                                          69 307     23892                      34.5%                                              47.4%                       33.0%   19.5%
  Taiwan                                             52 514     28123                      53.8%                                              18.6%                       28.9%   52.0%
  Sudan                                              44 413     7332                       16.6%                                              94.9%                       2.1%    3.0%
  Argentina                                          32 346     16263                      50.4%                                              24.9%                       33.2%   41.5%
  Ivory Coast                                        24 563     5015                       20.4%                                              78.6%                       11.6%   9.8%
  Colombia                                           22 258     5036                       22.8%                                              32.5%                       19.1%   47.6%
  Venezuela                                          21 645     10584                      48.9%                                              14.5%                       28.1%   57.4%
  Nigeria                                            19 904     6709                       36.2%                                              61.7%                       21.6%   15.2%
  Angola                                             17 481     6022                       34.5%                                              67.8%                       19.2%   13.0%
  Cameroon                                           16 093     4595                       29.2%                                              59.7%                       22.8%   17.1%
  Kenya                                              14 847     3647                       24.6%                                              55.4%                       20.3%   24.3%
  Bangladesh                                         11 418     5401                       47.3%                                              43.5%                       29.5%   27.0%
  Viet Nam                                           10 993     3154                       28.7%                                              47.8%                       19.6%   32.5%
  Italy[\*\*](#tblfn2){ref-type="table-fn"}          10 076     3099                       30.8%                                                                                     
  Zambia                                             9 607      2438                       25.9%                                              70.0%                       17.9%   11.0%
  Armenia                                            9 199      3114                       33.9%                                              47.0%                       40.7%   12.2%
  Brazil                                             7 260      3396                       47.0%                                              27.2%                       28.8%   43.2%
  Ecuador                                            6 984      1968                       28.2%                                              22.7%                       19.6%   57.7%
  United Arab Emirates                               6 193      1867                       30.2%                                              43.5%                       22.9%   33.6%
  Georgia                                            6 144      3744                       60.9%                                              25.6%                       49.7%   24.7%
  Nepal                                              5 972      1456                       24.4%                                              62.4%                       17.0%   20.6%
  Poland                                             5 834      2061                       35.3%                                              47.3%                       25.8%   26.8%
  Russia                                             5 660      2709                       47.9%                                              27.8%                       40.4%   31.8%
  Pakistan[\*\*](#tblfn2){ref-type="table-fn"}       5 333      1880                       36.4%                                                                                     
  United Kingdom & Ireland                           7 714      3099                       40.3%                                              45.4%                       22.0%   32.3%
  Chile                                              4 754      1153                       24.3%                                              56.6%                       14.1%   29.3%
  Mozambique                                         4 454      1371                       31.1%                                              80.2%                       12.1%   7.5%
  Malaysia                                           4 116      1317                       32.4%                                              36.1%                       25.7%   37.6%
  Malawi                                             4 009      849                        22.3%                                              82.1%                       9.2%    8.7%
  Hungary                                            3 967      2052                       51.8%                                              26.9%                       32.5%   40.5%
  Spain                                              3 849      1923                       50.0%                                              21.2%                       26.7%   52.1%
  Congo                                              3 842      1576                       41.0%                                              60.7%                       25.9%   13.4%
  Australia                                          3 817      1188                       31.2%                                              49.7%                       20.1%   30.1%
  South Africa                                       3 250      795                        24.5%                                              57.7%                       19.7%   22.3%
  Austria                                            2 711      1704                       62.9%                                              44.9%                       35.0%   20.1%
  Cabo Verde                                         2 630      760                        29.0%                                              30.5%                       29.6%   39.1%

Note figures for India include only those with all 3 readings available as multiple imputation not used on subset of data from India

Medication use not recorded, so percentages not on medication and uncontrolled/controlled on medication excluded.

Given a common protocol for the MMM17 campaign, the background and methods of the project are essentially the same across countries but variations in the sources of the convenience samples included, and other logistical issues are apparent and critical to the interpretation of local data. Consequently, we provide keywords which are applicable to all the national papers included.

Methodological differences
==========================

Inevitably, given 39 separate analyses, chance variation from the global findings will occur and it is inappropriate to carry out some analyses where sample sizes do not permit. Furthermore, the data quality was inadequate in some cases due to logistical problems collecting and recording the data. Not all survey questions were asked in every country, and three BP readings were not universally taken due to local differences in protocol or individual screenee factors.

Our original analysis made use of multiple imputations to impute the mean of the 2nd and 3rd BP reading, where this was missing.[@suz055-B2] The necessity for doing this in drawing comparisons across individuals was underlined by our finding of significant differences among the 1st, 2nd, and 3rd BP readings. Imputations were based on a single BP reading, accounting for the age, gender, and geographical region of the participant. Our previous analyses showed that the biggest determinant of the mean of the 2nd and 3rd readings was a single BP reading. For country-level analyses, we have used the same imputed data from our global study, which may result in an 'averaging' of any country-specific effects. While unique imputations for each country would be ideal, in most cases, there were insufficient data to allow this. Imputation was not possible for all individuals (where either age or gender were missing), so the denominators used in analysis are in many cases less than the total number screened.

Associations of BP with age, gender, and body mass index display a very similar pattern at the country level to those globally. The country papers in this supplement focus on those measures of association which differ to the global results or for which there is particular local interest.

Challenges to MMM17
===================

Many challenges were faced in the set-up and running of MMM17. From formulating the idea of MMM in September 2016, ISH had 7 months to prepare for MMM17. Critically, would-be national collaborators had to be identified using the International Forum of ISH, the World Hypertension League, National Hypertension or Cardiovascular Societies, the Regional Advisory Groups of ISH and word of mouth. Once identified, these individuals were charged with arranging the logistics at their national level---particularly getting ethical clearance and identifying screening sites and the volunteer workforce.

Several countries experienced delays in being granted ethical approval, which limited the scale of their involvement. Logistical issues were faced with distributing the BP machines kindly donated by OMRON, with customs charges and delivery delays, which again caused local problems for screening sites.

A limited set of questions were asked of each participant. While more data would have generated greater insight, this was balanced against the added time to administer the survey, and a limitation to the number possible to screen. Temperature at the screening site was included, but following an investigator meeting, it became apparent that there were inconsistencies in whether room or outside temperature were recorded, so this was not included in analysis.

Data collected from around the world came through in various formats, predominantly spreadsheets, which were updated from handwritten entries in the field. Although an online app was available, this was difficult for many study sites to access, and used for only 8% of participants. The use of free-text fields in spreadsheets created a huge amount of work in data cleaning, which was carried out both locally and centrally, with some data unfortunately not possible to salvage. These logistical difficulties resulted in our only being able to lock the database and initiate analyses in January 2018---nominally 7 months after MMM17 ended!

Limitations
===========

The results presented here are based on a real world, opportunistic screening campaign, and recruitment was not randomized. For this reason, proportions with hypertension should not be taken as the true underlying prevalence but should be viewed within the local context and a reflection of who would *actually* present for screening. Despite this, in reviewing the results reported in this supplement, it is remarkable how often the authors report that the proportion of those found to be hypertensive, those untreated or those uncontrolled on treatment are similar to other nationally representative samples previously reported.

A further shortcoming is that, by design, as a cross-sectional survey, we do not have data on individual outcomes. Those found to have untreated hypertension, or uncontrolled BP on treatment, were given verbal and written advice that was specific to each country. As we know, dietary and lifestyle changes together can bring about average improvements in systolic BP in the order of 10 mmHg, but we lack data on what happened after advice was supplied. We hope to expand MMM to include a cohort component in some, if not all, countries from 2019 onwards, to allow us to monitor whether intervention resulted in any change for the individual.

Prospects for the MMM campaign
==============================

The success of MMM17 in terms of numbers of countries involved, number of people screened, and number of people detected who had untreated or inadequately treated hypertension made clear that MMM was a pragmatic interim solution to the shortfall of BP screening programmes around the world. As long as volunteer investigators can be found around the world supported by the modest funding involved, MMM should continue on an annual basis.

In 2018, over 1.5 million adults were screened and the data quality was improved in part due to a redesigned spreadsheet template and updated bespoke App which functioned offline/without internet connection. Analyses of these data are complete and the 2019 campaign is in advanced planning stages. Ultimately, we want to use the data generated to influence governments and health policy makers to provide more emphasis and support for BP screening and the prevention and management of raised BP.
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